Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avanir Abreva Cold Sore/Fever Blister Cream Approved By FDA

This article was originally published in The Tan Sheet

Executive Summary

Avanir Pharmaceuticals' 10% docosanol cream was approved July 25 for the treatment of cold sores and fever blisters. The product, which FDA's approval letter indicates will be marketed as Abreva Cream, will be the first FDA-approved OTC cold sore and fever blister treatment.
Advertisement

Related Content

First-In-Class PreHistin Could Challenge Antihistamines In Two Years – Exec
First-In-Class PreHistin Could Challenge Antihistamines In Two Years – Exec
Pure Lip Cold Sore Aids Promoted As "The Cold Sore Solution"
Abreva Shortened Healing Time, Duration Of Cold Sores Stressed In Promos
Avanir
Avanir
Avanir grant
SB Aquafresh 17% Sales Increase Freshens Up Second Quarter Results
Avanir
Avanir

Topics

Advertisement
UsernamePublicRestriction

Register

PS091475

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel